⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844716 | 0.83 | — | — | |
| SCHEMBL16311819 | 0.75 | — | — | |
| SCHEMBL247652 | 0.75 | — | — | |
| SCHEMBL156190 | 0.74 | — | — | |
| SCHEMBL1205413 | 0.74 | — | — | |
| SCHEMBL1828211 | 0.74 | — | — | |
| SCHEMBL31013217 | 0.74 | — | — | |
| SCHEMBL845963 | 0.74 | — | — | |
| SCHEMBL17285647 | 0.74 | — | — | |
| SCHEMBL31452225 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102898358-A | Preparation method of fluoropyridine compounds | SHANGHAI TITAN TECHNOLOGY CO LTD | 2013-01-30 | — | — | CN | claimed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-04-09 | — | — | US | disclosed |
| EP-4720041-A2 | N-(1H-INDOL-2-YL)METHYL)-4-ETHYNYL-PICOLINAMIDE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Allorion Therapeutics Inc (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12459904-B2 | Process for preparing carbamoyloxymethyl triazole cyclohexyl acid compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-04 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250296939-A1 | BENZOTHIOPHENE COMPOUND | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2025-09-25 | — | — | US | disclosed |
| CN-101238116-A | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-08-06 | — | — | CN | disclosed |
| WO-2008064829-A2 | NOVEL AMINOTHIENOPYRIDINONE DERIVATIVES PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF | UCB PHARMA, S.A. (BE) | 2008-06-05 | — | — | WO | disclosed |
| EP-1899323-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| CN-101124205-A | Substituted aminopyridines and uses thereof | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | CN | disclosed |
| EP-1831170-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| CN-1871001-A | Alkynes III | ASTRAZENECA AB (SE) | 2006-11-29 | — | — | CN | disclosed |
| WO-2006123113-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | WO | disclosed |
| EP-1677788-A1 | ALKYNES III | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005044265-A1 | ALKYNES III | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |